SARS-CoV-2 associated Miller-Fisher syndrome or polyneuritis cranialis.

Table 1

SARS-CoV-2-associated MFS reported as per the end of March 2021

Age (y)	Sex	Onset	LOO (d)	Subtype	CIC	Comorbitities	IVIG	AV	Recovery	Country	Reference
50	M	A	3	MFS, PNC	No	No	Yes	No	Yes	Spain	Gutiérrez-Ortiz et al. (2020)
39	M	A	3	MFS, PNC	No	No	No	No	Yes	Spain	Gutiérrez-Ortiz et al. (2020)
61	M	A	10	MFS	No	No	S	No	Yes	Spain	Juliao Caamaño and Alonso (2020)
36	M	A	4	MFS	nr	nr	Yes	No	Yes	USA	(Lantos et al. 2020)
51	F	A	14	MFS	nr	nr	Yes	No	Partial	Spain	(Reyes-Bueno et al. 2020)
34	M	A	4	PNC	nr	Strabism	Yes	No	Partial	USA	(Dinkin et al. 2020)
71	F	A	Days	PNC	nr	AHT	No	No	Partial	USA	(Dinkin et al. 2020)
49	M	A	14	MFS	No	Crohn’s disease	Yes	Yes	Partial	USA	(Lowery et al. 2020)
55	M	A	20	AIDP/MFS	No	nr	Yes	No	Partial	Italy	(Garnero et al. 2020)
63	M	A	1	MFS	nr	nr	No	No	Partial	UK	(Ray 2020)
61	M	A	nr	MFS	No	nr	Yes	No	Yes	Germany	(Senel et al. 2020)
50	M	B	Days	MFS	No	DM, heroin, obesity	Yes	Yes	Death	USA	(Kajani et al. 2021)
50	F	A	16	MFS	nr	No	Yes	No	Yes	Italy	(Manganotti et al. 2020)

A onset of GBS after onset of non-neurological manifestations, AHT arterial hypertension, AV artificial ventilation, B onset of GBS before onset of non-neurological manifestations, CIC CoV2 in CSF, DM diabetes, F female, LOO latency between onset of GBS and COVID-19, respectively, vice versa, M male, nr not reported, PNC polyneuritis cranialis, S steroids